- WKN: -
- Land: Deutschland
Nachricht vom 01.12.2021 | 09:30
GBC AG: GBC Research initiates coverage of IGEA Pharma N.V.: Target price EUR 1.05; BUY rating
DGAP-News: GBC AG
/ Key word(s): Study
- Realignment to European CBD market
- Aggressive growth expected with strong scaling effects
- EUR 170.15 million revenue and EUR 105.25 million EBITDA expected in 2023
- Company to present at MKK Munich Capital Markets Conference on Dec. 8, 2021 from 10:50 a.m. -11:25 a.m
Augsburg, December 01, 2021 - GBC Research has started coverage of IGEA Pharma N.V. (ISIN NL0012768675). The company is currently undergoing a realignment and will address the high-growth European CBD market in the future. With a focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. After the start of production in 2022, sales should be able to grow rapidly with a very attractive EBITDA margin. We expect IGEA Pharma to generate revenues of EUR 170.15 million in 2023 with EBITDA of EUR 105.25 million. Based on our DCF model, we have determined a fair value of EUR 1.05 (CHF 1.13) per share and assign a BUY rating.
The reorientation of IGEA Pharma is based on a reverse IPO. For this purpose, Blue Sky Natural Resources Ltd. was contributed to IGEA Pharma on September 27, 2021 through a capital increase in kind. The business model is now to change fundamentally. The wellness and prevention sector is to be addressed with a focus on CBD. The goal is to become the quality and cost leader in CBD in Europe. To this end, a GMP-compliant facility is being built in Switzerland. To achieve the highest quality standard, the supercritical CO2 extraction process will be used. For this purpose, a proprietary system has been developed. Due to the very high quality, the product shall be sold at significantly higher prices compared to CBD extracted by solvent-based methods. CBD is to be marketed exclusively B2B in wholesale. According to management, the selling price may be around CHF 8,500 / kg. Based on this assumption, we forecast a substantial sales and earnings development. With the proprietary supercritical CO2-extraction technology, other markets can be developed in the medium term, such as vanilla, roses or rosemary.
In addition, the Company will present at the MKK Munich Capital Market Conference (online) on
08.12.21 from 10:50 to 11:25 a.m. in the virtual room GBC II.
Interested investors can participate under the following link:
The meeting ID is: 840 9084 0082
The identification code is: 794739
Contact for queries
GBC AG: Invitation to the 3rd International In ...
3. International Investment Forum am 19. Mai 2 ...
33. MKK - Münchner Kapitalmarkt Konferenz am 0 ...
Jetzt zur 33. MKK - Münchner Kapitalmarkt Konf ...
GBC Management Interview with Paul Echt, CFO o ...
Events im Fokus
1./2. Juni 2022: Fachkonferenz Immobilien & Software | IT
13./14. Juli 2022: Fachkonferenz Beteiligungsgesellschaften & Consumer/Leisure
12./13. Oktober 2022: Fachkonferenz Finanzdienstleistungen/Technologie
Der AKTIONÄR News
27. Mai 14:29 TUI: Darum kommt die Aktie nicht auf die Beine
27. Mai 14:55 Dell: Diese Zahlen räumen mit den Sorgen auf
27. Mai 17:00 Kommentar: Warum Bärenmärkte gut sind
27. Mai 18:02 Twitter-Übernahme: Nun hat Elon Musk Ärger mit der SEC
FY 2021/22 Preliminary Results
02. Juni 2022
Original-Research: SunMirror AG (von Sphene Capital GmbH): Buy
27. Mai 2022